Expert Groups and Platforms

The purpose of CIMA-Q is to promote and potentiate Québec’s expertise in research on Alzheimer’s disease. The Consortium has set up expert groups and platforms whose mission is the:

  • Identification of reliable and sensitive predictive cognitive tests
  • Discovery of new neuroimaging markers
  • Identification of new biomarkers and therapeutic targets
  • Identification of risk factors and preventive factors

The «CIMA-Q group», as mentioned in publications or any other document, refers to the principal investigators and co-researchers, who participated in the drafting of the project as well as to the collaborators, who offer valuable support through their unique expertise. This group is composed of the following people:

Belleville, Sylvie Bocti, Christian
Duchesne, Simon Breitner, John
Gaudreau, Pierrette Calon, Frédéric
Gauthier, Serge Chertkow, Howard
Hudon, Carol Fuhrer, Rebecca
Kergoat, Marie-Jeanne Hébert, Sébastien
LeBlanc, Andréa Poulin, Stéphane
Mechawar, Naguib Soucy, Jean-Paul
Verret, Louis
Villalpando, Juan Manuel

Biomarkers and therapeutic targets

The ‘biomarkers and therapeutic targets’ team provides biological materials to researchers interested in discovering new molecular mechanisms and therapeutic targets and establishing a molecular prognosis for Alzheimer’s disease. …read more

Cognitive and neuropsychiatric markers

Recent studies suggest that the development of Alzheimer’s disease begins 5 to 15 years before the onset of memory, language and judgment disorders. One of the research challenges of research is to diagnose the disease as soon as possible, because when cognitive disorders are too important advanced, treatments are less effective. The objective of the ‘Cognition’ group is to set up a battery of tests and questionnaires that will have the ability to predict, in a person with no or slight mild symptoms, whether they will develop Alzheimer’s disease a few years later. To achieve this goal, researchers in the Cognition group will use tools to evaluate cognitive functioning (eg, memory, language), perception of cognitive decline, and some psychiatric symptoms (eg, depression, anxiety). …read more


Neuroimaging is a well-established and recognized technique for diagnosing Alzheimer’s disease and for facilitating prognosis in individuals with mild cognitive impairment. In this project, CIMA-Q aims to establish the relevance of neuroimaging in detecting even earlier signs and / or risk factors associated with Alzheimer’s disease in individuals with subjective cognitive complaints, which are often the first manifestations of dementia. …read more

Protective and risk factors

It has been proposed that Alzheimer’s disease develops when the summing up of risk factors surpasses the self-healing capacity of the brain. Although age is the best predictor of the disease, several other factors, preventive or aggravating, have been identified. Comorbidities, or the presence of diseases other than Alzheimer’s, such as cardiovascular disease, type 2 diabetes, hypertension, high cholesterol, stroke or mini-stroke, chronic inflammatory conditions and episodes of clinical depression have been associated with accelerated cognitive decline and dementia. …read more

Clinical and population cohorts

The CIMA-Q project involves the longitudinal study (over several years) of about 350 people aged 65 or older at different stages of evolution of brain function problems (eg memory, orientation, language, attention, or other). Thus, cognitively healthy participants, people with subjective cognition complaints, people with mild cognitive impairment and people with Alzheimer’s dementia will be studied for several years to better characterize the evolution of memory problems and the progression of Alzheimer’s disease. …read more

Brain Bank

Brain tissue studies are essential for understanding mental or neurological disorders. Access to such tissues allows researchers to further learn about the causes of different brain diseases or to develop effective treatments for Alzheimer’s disease, depression, schizophrenia, etc. The primary mission of the Douglas-Bell Canada Brain Bank is to provide the scientific community with brain samples that are of optimal quality and preservation for research. This will help the acquisition of scientific knowledge to treat, cure and prevent diseases and brain disorders. …read more